Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma

Table 3 Results of checkpoint inhibitors in treatment of patients with metastatic clear cell renal cell cancer

Drug/Study	Phase	Indication	Follow-up	Results	Ref.
Pembrolizumab (Keynote 427)	II	mnccRR	11	ITT ORR 24.8%; ORR Papillary vs phromophobe vs unclasified 25.4% vs 9.5% vs 34.6%; 12 mo PFS 22.8%; 12 mo OS 72%	[50]
Nivolumab (Checkmate 374)	IIIb/IV	mnccRR	11	ITT; OS 16,3 mo; PFS 2,2 mo; ORR 13,6%	[51]
Atezolizumab/Cabozantinib (Cosmic 021)	Ib	mnccRR	9,2	ITT ORR 33%	[52]
Durvalumab/Savolitinib (Calypso)	Ib/II	mnccRCC-papillaryuntreated or previously treated	8,9	ITT; ORR 27%; PFS 3,3 mo; Untreated ORR 29%; PFS 12,2	[53]